0001127602-20-006488.txt : 20200219 0001127602-20-006488.hdr.sgml : 20200219 20200219165725 ACCESSION NUMBER: 0001127602-20-006488 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200214 FILED AS OF DATE: 20200219 DATE AS OF CHANGE: 20200219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: STAAB THOMAS R II CENTRAL INDEX KEY: 0001230708 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 20630754 MAIL ADDRESS: STREET 1: C/O INSPIRE PHARMACEUTICALS, INC. STREET 2: 4222 EMPEROR BLVD., SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-02-14 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001230708 STAAB THOMAS R II 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 Senior Vice President and CFO Emp. Stock Option (Right to Buy) 11.13 2020-02-14 4 A 0 31500 0 A 2020-02-14 2024-12-22 Common Stock 31500 31500 D On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. /s/ Alane P. Barnes, by power of attorney 2020-02-19